Compare GSK plc (GSK) vs Novagold Resources Inc. (NG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Novagold Resources Inc. — how do they compare? GSK plc trades at $48.54 (market cap $92.78B), while Novagold Resources Inc. trades at $6.32 (market cap $2.90B). The key difference: GSK plc is far larger — about 32× Novagold Resources Inc.'s market cap, and GSK plc pays a 3.92% dividend while Novagold Resources Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Novagold Resources Inc. for 0 Days on average.
| GSK | NG | |
|---|---|---|
Market Cap | $92.78B | $2.90B |
Volume | 5,756,402 | 3,973,464 |
Sector | Health | Basic Materials |
52-Week High | $61.18 | $14.20 |
52-Week Low | $43.24 | $5.18 |
Typical Hold Time | 93 Days | 0 Days |
Enterprise Value | $112.77B | $2.74B |
Dividend Yield | 3.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $47.87, up 2.02% today, with a bearish technical signal despite recent earnings beats. The company shows strong profitability with 72.73% gross margins and 14.52% net income margin, supported by consistent revenue growth from $32.67B in 2025. Recent developments include a $750M cancer therapy acquisition and strategic focus on oncology expansion.
GSK presents a mixed outlook with solid fundamentals and strategic pipeline investments offset by technical weakness and patent cliff concerns. The stock offers value at 14.84 P/E but faces execution risks in oncology growth and HIV patent expirations. Analyst consensus leans cautious with 55% hold ratings.
NovaGold Resources (NG) trades at $6.63, down 1.49% today, as the company navigates its development phase for the Donlin Gold project. The stock shows mixed earnings performance with recent quarterly losses but beats expectations in two of the last four quarters. Financials reveal negative profitability metrics with ROE at -32.81% and net income of -$94.66M for 2025, though cash flow remains positive due to financing activities. Recent news highlights the company's move to acquire full ownership of Donlin Gold, a major Alaska gold project.
The outlook for NG hinges on successful development of Donlin Gold, with 100% analyst buy ratings signaling strong Wall Street confidence. However, significant execution risks exist given negative earnings and substantial capital requirements. Investors face volatility from gold price fluctuations and project development timelines, making this suitable for those with high risk tolerance seeking exposure to a major gold development story.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Novagold Resources Inc.
NovaGold Resources Inc. is a mineral exploration and development company that holds a majority interest in the Donlin Gold project, an undeveloped gold deposit in Alaska.
Read more on NG →
